In prostate cancer, the percentage of bone metastases at presentation was higher in T3-4 than T0-2 (10.1% vs 3.4%) and N1 compared to N0 (38.1% vs 3.3%) (p < 0.001), increased from 0.2% in patients with International Society of Urological Pathology (ISUP) Gleason score group 1 to 22.8% in group 5 and from 0.7% in patients with PSA < 10 to 19.5% in those with PSA ≥ 98 ng/dL (p < 0.001). The gene discussed is KLK3; the disease is Familial prostate cancer.